Cost-benefit approach in evaluating investment into donor action: The German case

Transplant International

Volumn 16, Issue 5, 2003, Pages 321-326

  Roels, Leo ^a   Kalo, Zoltán ^b   Boesebeck, Detlef ^c   Whiting, James ^d   Wight, Celia ^e  

^a Donor Action Foundation   (Belgium)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Deutsche Stift Organtransplantation   (Germany)

^d MAINE MEDICAL CENTER   (United States)

^e Donor Action Foundation Secretariat   (Canada)

Author keywords

Cost benefit cost effectiveness analysis; Organ donation; Quality assurance

Indexed keywords

ARTICLE; COMPUTER ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; DIALYSIS; FINANCIAL MANAGEMENT; GERMANY; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL;

COST SAVINGS; COST-BENEFIT ANALYSIS; GERMANY; HUMANS; INTENSIVE CARE UNITS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; QUALITY ASSURANCE, HEALTH CARE; RENAL DIALYSIS; TISSUE AND ORGAN PROCUREMENT; WAITING LISTS;

EID: 0038409926     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2003.tb00307.x     Document Type: Article

References (39)

1. Baxter D (2001) Beyond comparison: Canada's organ donation rate in an international context. The Urban Futures Institute (eds), Vancouver, Canada
2. Bundespflegesatzverordnung fuer Krankenhaeuser in der Fassung vom 1.1.2001. Bundesministerium fuer Gesundheit und Soziale Sicherheit, Bonn, Germany
3. David S, Cambi V (1995) Hamodialysis and peritoneal dialysis. Medicine 23:151-155
4. de Wit GA, Ramstein PG, de Charro FT (1998) Economic evaluation of end-stage renal disease treatment. Health Policy 44:215-232
5. Eggers P (1992) Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 12:284-289
6. Elinder CG, Jones E, Briggs JD, Mehls O, Mendel S, Piccoli G, Rigden SP, Pinto dos Santos J, Simpson K, Tsakiris D, Vanrenterghem Y (1999) Improved survival in renal replacement therapy in Europe between 1975 and 1992. An ERA-EDTA Registry study. Nephrol Dial Transplant 14:2351-2356
7. Eurotransplant International Foundation (2000) In: Persijn GG, Cohen B (eds) Annual Reports 1992-1999. Leiden, the Netherlands
8. Evans RW, Kitzmann DJ (1998) An economic analysis of kidney transplantation. Surg Clin North Am 78:149-174
9. Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG (1985). The quality of life of patients with end-stage renal disease. N Eng J Med 312:553-559
10. Frei U, Schober-Halstenberg HJ (1999) "Nierenersatztherapie in Deutschland" Bericht über Dialysebehandlung und Nierentransplantation in Deutschland. QuasiNiere pp 1-31
11. Gudex CM (1995) Health-related quality of life in end-stage renal failure. Qual Life Res 4:359-366
12. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D (2000) Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342:605-612
13. Holohan TV (1996) Cost-effectiveness modeling of simultaneous pancreas-kidney transplantation, Int J Technol Assess Health Care 12:416-424
14. Joint Council of Europe (2001) Eurostat demographic data collection. Statistics in focus. In: European Community (eds) Eurostat/E4, Luxemburg, http//www.europa.int/comm/eurostat/3:3
15. Kalo Z. Jaray J. Nagy J (2001) Economic evaluation of transplantation compared to haemodialysis in patients with end-stage renal disease: the Hungarian experience. Prog Transplant 11:188-193
16. Karlberg I, Nyberg G (1995) Cost effectiveness studies of renal transplantation. Int J Technol Assess Health Care 11:611-622
17. Klarman HE, Francis JO, Rosenthal GD (1968) Cost effectiveness analysis applied to the treatment of chronic renal disease. Med Care 6:48-54
18. Kupsch S, Kern AO, Hallauer JF (1998) Vesorgung von Patienten mit Nierenersatztherapie in Deutschland, IGSF, Kiel
19. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N (1996) A study of the quality of life and cost utility of renal transplantation. Kidney Int 50:235-242
20. Ludbrook A (1981) A cost-effectiveness analysis of the treatment of chronic renal failure. Appl Econ 13:337-350
21. Medin C, Elinder CG, Hylander B, Blom B, Wilczek H (2000) Survival of patients who have been on a waiting list for renal transplantation. Nephrol Dial Transplant. 15:701-704
22. Meier-Kriesche HU, Kaplan B (2001) Death after graft loss: a novel endpoint for renal transplantation. Am J Transplant [Suppl 1]:377
23. Meier-Kriesche HU, Ojo AO, Port FK, Arndorfer JA, Cibrik DM, Kaplan B (2001) Surviral improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 12:1293-1296
24. Michel BC, van Hout BA, Bonsel GJ (1994) Assessing the benefits of transplant services, Baillieres Clin Gastroenterol 8:411-423
25. Nagel E. Niechzal M (1999) Bewertung chirurgischer Therapien: angemessennotwendig-zweckmässig. Springer. Berlin Heidelberg New York
26. Organ Donation and Transplantation in Germany. 5th Report (1999) Deutsche Stiftung Organtransplantation (eds) (DSO), Neu-Isenburg, Germany
27. Parsons D, Harris D (1997) Review of quality of life in chronic renal failure. Pharmacoeconomics 12:140-160
28. Pastan S, Bailey J (1998) Dialysis therapy. N Engl J Med 14:1428-1437
29. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K (1993) Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 270:1339-1343
30. Roels L, Wight C (2001) Donor Action: an international initiative to alleviate organ shortage. Prog Transplant 11:90-97
31. Russell JD, Beecroft ML, Ludwom D, Churchill (1992) The quality of life in renal transplantation - a prospective study. Transplantation 54:656-660
32. Scheld HH, Deng MC, Hammel, D, Roeder N, Roetker J (1994) Kosten/Nutzen-Relation der Herztransplantation, Z Kardiol 83.139-149
33. Smits JM, van Houvelingen HC, De Meester J, Le Cessie S, Persijn GG, Claas FH, Frei U (2000) Permanent detrimental effect of nonimmunological factors on long-term renal graft survival: a parsimonious model of time-dependency. Transplantation 70:317-323
34. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338
35. USRDS annual data report (2000) US Department of Health and Human Services, Health Resources and Services Administration, Office of Special Programs, Division of Transplantation, Rockville, Md; United Network for Organ Sharing, Richmond, Va
36. van Enckevort PJ, ten Vergert EM, Bonsel GJ, Geertsma A, van der Bij W, de Boer WJ, Koopmanschap MA, Al MJ, Rutten FF (1998) Technology assessment of the Dutch Lung Transplantation Program. Int J Technol Assess Health Care 14:344-356
37. Wight C, Cohen B, Beasley C, Miranda B, Deblander G (1998) Donor Action: a systematic approach to organ donation. Transplant Proc. 30:2253-2254
38. Wight C, Cohen B, Roels L, Miranda B (2000) Donor Action: a quality assurance programme for intensive care units which increases organ donation. Intensive Care Med 15:104-114
39. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725-1730